Fig. 2

Well-being in patients with immunodeficiency disorders taking antidepressants, before and after a 1 year vitamin D study. In patients with a better well-being during the study (n = 10) there was an average increase in 25-hydroxyvitamin D (25-OHvitD) levels (p < 0.001, Wilcoxon signed rank test). Four patients could terminate their antidepressant therapy during the study (red lines). In patients stating no difference (n = 6) or worse well-being (n = 6) there was no change in average 25-OHvitD levels (p = not significant)